—
Non-Alcoholic Steatohepatitis (NASH) Drugs Market 2019-2025Description: -
Nonalcoholic steatohepatitis is a form of liver disease that develops in patients who are not alcoholic. The major feature in NASH is fat deposition in the liver, along with inflammation and damage to the liver. Most patients with NASH are not aware that they are suffering from a liver problem. However, NASH can become severe and can lead to cirrhosis, in which the liver is permanently damaged.
Scope of the Report:
This market is boosted by the growing prevalence of diabetes and obesity, and high investments for research and development, which leads to rising demand for NASH and others nonalcoholic fatty liver diseases (NAFLD) therapies in the market. As per the regional analysis, the well-established healthcare infrastructure with the high adoption rate of new technologies and increasing research activities, makes North America dominate this market.
In 2018, the global Non-Alcoholic Steatohepatitis (NASH) Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
Free Sample Report @ https://www.wiseguyreports.com/sample-request/4000402-global-non-alcoholic-steatohepatitis-nash-drugs-market-size
The major manufacturers covered in this report
AstraZeneca
Conatus Pharmaceuticals
Enzo Biochem
Galmed Pharmaceuticals
Genfit
Gilead
Horizon Pharma
Immuron
Intercept Pharmaceuticals
Novo Nordisk
Market segment by Type, the product can be split into
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc
Market segment by Application, split into
Hospital Pharmacy
Online Provider
Retail Pharmacy
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Non-Alcoholic Steatohepatitis (NASH) Drugs status, future forecast, growth opportunity, key market and key players.
To present the Non-Alcoholic Steatohepatitis (NASH) Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
Leave a Query @ https://www.wiseguyreports.com/enquiry/4000402-global-non-alcoholic-steatohepatitis-nash-drugs-market-size
Major Key Points in Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Vitamin E & Pioglitazone
1.4.3 Obeticholic Acid (OCA)
1.4.4 Elafibranor
1.4.5 Selonsertib & Cenicriviroc
1.5 Market by Application
1.5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacy
1.5.3 Online Provider
1.5.4 Retail Pharmacy
1.6 Study Objectives
1.7 Years Considered
…………….
12 International Players Profiles
12.1 AstraZeneca
12.1.1 AstraZeneca Company Details
12.1.2 Company Description and Business Overview
12.1.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.1.5 AstraZeneca Recent Development
12.2 Conatus Pharmaceuticals
12.2.1 Conatus Pharmaceuticals Company Details
12.2.2 Company Description and Business Overview
12.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.2.5 Conatus Pharmaceuticals Recent Development
12.3 Enzo Biochem
12.3.1 Enzo Biochem Company Details
12.3.2 Company Description and Business Overview
12.3.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.3.5 Enzo Biochem Recent Development
12.4 Galmed Pharmaceuticals
12.4.1 Galmed Pharmaceuticals Company Details
12.4.2 Company Description and Business Overview
12.4.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.4.5 Galmed Pharmaceuticals Recent Development
12.5 Genfit
12.5.1 Genfit Company Details
12.5.2 Company Description and Business Overview
12.5.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.5.5 Genfit Recent Development
12.6 Gilead
12.6.1 Gilead Company Details
12.6.2 Company Description and Business Overview
12.6.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.6.5 Gilead Recent Development
12.7 Horizon Pharma
12.7.1 Horizon Pharma Company Details
12.7.2 Company Description and Business Overview
12.7.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
12.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2014-2019)
12.7.5 Horizon Pharma Recent Development
Continued......
For Detailed Report Visit @ https://www.wiseguyreports.com/reports/4000402-global-non-alcoholic-steatohepatitis-nash-drugs-market-size
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd.
Address: Office No.528,Amanora Chambers,Magarpatta Road,Hadapsar,Pune-411028.
Phone: +1-646-845-9349
Website: https://www.wiseguyreports.com/
Release ID: 510806
Google
RSS